Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome.


Journal

European journal of nutrition
ISSN: 1436-6215
Titre abrégé: Eur J Nutr
Pays: Germany
ID NLM: 100888704

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 21 02 2018
accepted: 18 09 2018
pubmed: 27 9 2018
medline: 19 3 2020
entrez: 26 9 2018
Statut: ppublish

Résumé

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a common functional gastrointestinal disorder. Probiotics and synbiotics have been shown to improve symptoms of IBS, although mechanisms of action are currently not understood. We investigated the effects of a 4-week oral synbiotic treatment (OMNi-BiOTiC Synbiotics led to an increased microbial diversity in gastric (p = 0.008) and duodenal (p = 0.025) mucosal specimens. FACS analysis of mucosal immune cells showed a treatment-induced reduction of CD4 Our findings indicate that a short-course oral synbiotic trial may influence the human gastrointestinal tract in IBS-D patients on different levels which are region specific.

Identifiants

pubmed: 30251020
doi: 10.1007/s00394-018-1826-7
pii: 10.1007/s00394-018-1826-7
pmc: PMC6768888
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2767-2778

Commentaires et corrections

Type : CommentIn

Références

Appl Environ Microbiol. 2013 Sep;79(17):5112-20
pubmed: 23793624
Am J Gastroenterol. 2012 Nov;107(11):1740-51
pubmed: 22986438
Dtsch Arztebl Int. 2011 Nov;108(44):751-60
pubmed: 22163251
Gut. 2010 Mar;59(3):325-32
pubmed: 19091823
Appl Environ Microbiol. 2007 Aug;73(16):5261-7
pubmed: 17586664
Z Gastroenterol. 2011 Feb;49(2):237-93
pubmed: 21287438
Sci Rep. 2016 Jan 04;6:18507
pubmed: 26725514
Appl Environ Microbiol. 2016 Sep 16;82(19):5850-9
pubmed: 27451450
Aliment Pharmacol Ther. 1997 Apr;11(2):395-402
pubmed: 9146781
Clin Gastroenterol Hepatol. 2012 Oct;10(10):1096-100
pubmed: 22902773
Aliment Pharmacol Ther. 2008 Oct 15;28(8):994-1002
pubmed: 18671775
Cell Host Microbe. 2015 May 13;17(5):662-71
pubmed: 25865369
Genes Nutr. 2011 Aug;6(3):209-40
pubmed: 21617937
Gut. 2013 Oct;62(10):1456-65
pubmed: 22767422
Front Microbiol. 2016 Dec 20;7:2012
pubmed: 28066342
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
Neurol Neuroimmunol Neuroinflamm. 2017 Jun 14;4(4):e362
pubmed: 28638851
Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4
pubmed: 22426087
Immunol Lett. 2013 Feb;150(1-2):30-40
pubmed: 23352670
Gastroenterology. 2002 Jun;122(7):1778-83
pubmed: 12055584
Clin Gastroenterol Hepatol. 2016 Nov;14(11):1602-1611.e5
pubmed: 27266978
Med Microbiol Immunol. 2017 Feb;206(1):1-9
pubmed: 27704207
Nature. 2013 Aug 8;500(7461):232-6
pubmed: 23842501
ISME J. 2016 Mar;10(3):742-50
pubmed: 26394008
Nat Rev Dis Primers. 2016 Mar 24;2:16014
pubmed: 27159638
Nat Rev Immunol. 2012 Oct;12(10):728-34
pubmed: 23007572
J Neurogastroenterol Motil. 2011 Jul;17(3):252-66
pubmed: 21860817
World J Gastroenterol. 2015 Mar 14;21(10):3072-84
pubmed: 25780308
J Gastroenterol Hepatol. 2013 Oct;28(10):1624-31
pubmed: 23800182
Transplantation. 2015 Aug;99(8):1553-9
pubmed: 26193065
PLoS One. 2016 Jan 04;11(1):e0146312
pubmed: 26727003
J Nutr. 2014 Nov;144(11):1787-96
pubmed: 25332478
BMC Gastroenterol. 2016 Apr 27;16(1):51
pubmed: 27121286
Diabetes. 2011 Aug;60(8):2120-4
pubmed: 21646390
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Gut. 2017 Sep;66(9):1537-1538
pubmed: 28082316
Bioinformatics. 2010 Jan 15;26(2):266-7
pubmed: 19914921
ISME J. 2011 Feb;5(2):169-72
pubmed: 20827291
Gut. 2007 Feb;56(2):203-9
pubmed: 17005763
J Nutr. 2013 Dec;143(12):1872-81
pubmed: 24132573
J Microbiol Methods. 2003 Dec;55(3):541-55
pubmed: 14607398
Gut. 2015 Sep;64(9):1379-88
pubmed: 25209656
Am J Gastroenterol. 2014 Oct;109(10):1547-61; quiz 1546, 1562
pubmed: 25070051
Nat Rev Immunol. 2013 Jun;13(6):461-7
pubmed: 23681097
Gut. 2013 Aug;62(8):1160-8
pubmed: 22637702
Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16799-804
pubmed: 19805376
Nature. 2013 Dec 19;504(7480):446-50
pubmed: 24226770

Auteurs

Adrian Mathias Moser (AM)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
Theodor Escherich Laboratory for Microbiome Research, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.

Walter Spindelboeck (W)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
Theodor Escherich Laboratory for Microbiome Research, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.

Bettina Halwachs (B)

Theodor Escherich Laboratory for Microbiome Research, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, 8036, Graz, Austria.

Heimo Strohmaier (H)

Center for Medical Research, Medical University of Graz, Stiftingtalstraße 24, 8010, Graz, Austria.

Patrizia Kump (P)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
Theodor Escherich Laboratory for Microbiome Research, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.

Gregor Gorkiewicz (G)

Theodor Escherich Laboratory for Microbiome Research, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, 8036, Graz, Austria.

Christoph Högenauer (C)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria. christoph.hoegenauer@medunigraz.at.
Theodor Escherich Laboratory for Microbiome Research, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria. christoph.hoegenauer@medunigraz.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH